President Trump will restructure the Strategic National Stockpile and increase America's production of supplies; the National Institutes of Health (NIH) is testing a new combination therapy for coronavirus disease 2019; FDA officials issue warning on Abbott Laboratories' rapid response test.
President Trump and his administration plan to restructure the Strategic National Stockpile (SNS) to prepare for potential future pandemics, the Associates Press reports. The president will also sign an executive order providing authority to ramp up domestic industrial capabilities to produce SNS supplies, such as personal protective equipment, bringing this sector of manufacturing back to the United States. He said the measures are intended to reduce dependency on foreign supplies. The announcement came on the same day whistleblower Rick Bright testified in front of Congress claiming the administration failed to adequately prepare for the current pandemic.The National Institutes of Health (NIH) has begun studying a combination of hydroxychloroquine, a malaria drug, and azithromycin, an antibiotic, as a potential coronavirus disease 2019 (COVID-19) treatment, according to The Hill. The trial will be conducted on 2000 adult patients with COVID-19 to determine whether the combination can prevent hospitalization and death from the disease. However, a panel of doctors and experts assembled by the NIH warned against combining the 2 medications outside of the clinical trial, due to potentially harmful adverse effects, including heart rhythm problems.Federal health officials at the FDA issued a warning on the accuracy of Abbott Laboratories’ rapid COVID-19 test, currently used at thousands of hospitals and the White House, the Associated Press reports. Preliminary data suggest the 15-minute test can miss cases of COVID-19 and falsely clear infected patients. On May 13, investigators at New York University first reported research indicating the test can miss up to half of infections flagged by a rival test, produced by Cepheid. However, the research has not been peer reviewed and was based on around 100 patients. The test is used daily to monitor President Trump and Coronavirus Task Force members.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More